Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-585 in Relapsed/Refractory Multiple Myeloma
NCT03318861Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of KITE-585 in multiple myeloma (MM) (5 arms), sponsored by Kite Pharma. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Oct 2017; status: terminated.
02
Drugs
KITE-585
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03318861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318861.